Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)

NCT05879757 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05879757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)
Lead sponsor
Takeda
Phase
Observational
Overall status
Recruiting
Start date
October 17, 2023
Completion date
February 16, 2027
Enrollment
75 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, secondary immunodeficiency (sid)